View ValuationTerumo 향후 성장Future 기준 점검 1/6Terumo (는) 각각 연간 11.6% 및 6.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 10.9% 로 예상됩니다.핵심 정보11.6%이익 성장률11.98%EPS 성장률Medical Equipment 이익 성장16.1%매출 성장률6.1%향후 자기자본이익률10.91%애널리스트 커버리지Good마지막 업데이트26 May 2026최근 향후 성장 업데이트공시 • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.모든 업데이트 보기Recent updates공시 • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.공시 • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026공시 • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026공시 • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.공시 • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.공시 • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.공시 • Sep 19Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025공시 • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.공시 • Jun 24Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025공시 • Jun 03Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration CatheterTerumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies.공시 • May 28Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent SystemTerumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025.공시 • May 14Terumo Corporation, Annual General Meeting, Jun 24, 2025Terumo Corporation, Annual General Meeting, Jun 24, 2025.공시 • Apr 17Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerTerumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.공시 • Mar 20Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025공시 • Dec 12Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025공시 • Dec 03Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support CatheterTerumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist.공시 • Sep 25Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024공시 • Aug 30Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury.공시 • Jun 03Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024공시 • May 29Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring SystemTerumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.공시 • Mar 17Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024공시 • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.공시 • Feb 07Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago.공시 • Dec 14+ 2 more updatesShinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024Terumo Corporation announced that it has resolved at the Board of Directors held on December 14, 2023 to change the Executive Officers as. Shinjiro Sato's designation will be changed from President and CEO to the new position of Director and Corporate Advisor (As of April 1, 2024). Shinjiro Sato, with completion of his term, is planned to leave the director's position at the Annual General Meeting of Shareholders to be held on June 26, 2024, and to remain as corporate advisor.공시 • Dec 03Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024공시 • Oct 01Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023공시 • Aug 10Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury.공시 • Jun 21Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023공시 • May 17+ 1 more updateTerumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation announced fiscal year-end dividend of JPY 21.00 per share for the fiscal year ended March 31, 2023 against JPY 18.00 per share paid a year ago. Scheduled date to commence dividend payments is June 28, 2023.The company provided second quarter-end dividend guidance for the fiscal year ending March 31, 2024. For the second quarter-end, The company expects to pay JPY 22.00 against JPY 19.00 per share paid a year ago.The company provided year-end dividend guidance for the fiscal year ending March 31, 2024. For the year-end, The company expects to pay JPY 22.00 against JPY 21.00 per share a year ago.공시 • May 16Terumo Corporation, Annual General Meeting, Jun 27, 2023Terumo Corporation, Annual General Meeting, Jun 27, 2023.공시 • Feb 09Terumo Corporation Revises Dividend Guidance for Fiscal Year Ending March 31, 2023Terumo Corporation decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows. The company revised dividend forecast to JPY 21.00 per share compared to the previous guidance of JPY 19.00 per share paid for the same period a year ago. Reason of the Revision: As a measure to secure high profit margins and sustainable growth, Terumo iscommitted to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term.공시 • Nov 10Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023이익 및 매출 성장 예측OTCPK:TRUM.Y - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/20291,394,119203,647162,636272,82593/31/20281,304,880181,467141,670251,262113/31/20271,227,606163,870128,395227,294123/31/20261,131,877135,914128,889230,852N/A12/31/20251,095,493127,903117,901208,469N/A9/30/20251,062,416130,671126,151211,891N/A6/30/20251,037,942124,930123,900207,742N/A3/31/20251,036,171116,978128,437210,802N/A12/31/20241,011,147125,099121,150199,400N/A9/30/2024986,674119,486114,170193,649N/A6/30/2024964,805117,71692,134170,598N/A3/31/2024921,863106,37467,556146,330N/A12/31/2023885,16799,04260,490133,870N/A9/30/2023860,76799,09635,316110,769N/A6/30/2023838,12189,47630,037105,606N/A3/31/2023820,20989,32545,363117,536N/A12/31/2022797,81487,29747,491117,976N/A9/30/2022761,98279,14665,356135,078N/A6/30/2022728,92783,31665,052134,924N/A3/31/2022703,30388,81367,362141,467N/A12/31/2021688,69690,36369,610146,371N/A9/30/2021675,18395,41469,307146,611N/A6/30/2021654,26091,16153,415133,980N/A3/31/2021613,84277,26838,573121,485N/A12/31/2020607,38176,91927,594117,626N/A9/30/2020604,91571,34220,121109,392N/A6/30/2020607,66976,42228,116115,667N/A3/31/2020628,89785,21133,995117,479N/A12/31/2019626,01689,868N/A109,420N/A9/30/2019621,76290,727N/A104,160N/A6/30/2019608,98784,170N/A100,340N/A3/31/2019599,48179,470N/A93,571N/A12/31/2018594,42984,305N/AN/AN/A9/30/2018588,16292,782N/A106,706N/A6/30/2018591,48393,095N/AN/AN/A3/31/2018587,77591,295N/A114,562N/A12/31/2017576,72585,888N/AN/AN/A9/30/2017553,66466,769N/A87,995N/A6/30/2017528,95760,406N/AN/AN/A3/31/2017514,16454,225N/A80,862N/A12/31/2016503,42939,014N/AN/AN/A9/30/2016510,96944,087N/A85,463N/A6/30/2016520,88546,282N/AN/AN/A3/31/2016525,02650,676N/A80,303N/A12/31/2015522,29648,528N/AN/AN/A9/30/2015515,36443,603N/A80,102N/A6/30/2015503,22144,580N/AN/AN/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TRUM.Y 의 연간 예상 수익 증가율(11.6%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: TRUM.Y 의 연간 수익(11.6%)이 US 시장(16.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: TRUM.Y 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: TRUM.Y 의 수익(연간 6.1%)이 US 시장(연간 11.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: TRUM.Y 의 수익(연간 6.1%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TRUM.Y의 자본 수익률은 3년 후 10.9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 19:10종가2026/05/27 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Terumo Corporation는 27명의 분석가가 다루고 있습니다. 이 중 12명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Steven LiuAletheia Analyst Network LimitedMasahiro NakanomyoBarclaysRitsuo WatanabeBofA Global Research24명의 분석가 더 보기
공시 • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.
공시 • May 15Terumo Corporation, Annual General Meeting, Jun 26, 2026Terumo Corporation, Annual General Meeting, Jun 26, 2026.
공시 • Apr 02Terumo Corporation to Report Q4, 2026 Results on May 15, 2026Terumo Corporation announced that they will report Q4, 2026 results on May 15, 2026
공시 • Dec 17Terumo Corporation to Report Q3, 2026 Results on Feb 13, 2026Terumo Corporation announced that they will report Q3, 2026 results on Feb 13, 2026
공시 • Nov 12+ 1 more updateTerumo Corporation Announces Dividend for the Second Quarter End of 2026, Payable on December 2, 2025; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026Terumo Corporation announced dividend for the second quarter end of 2026, payable on December 2, 2025; provided dividend guidance for the Fiscal year ending March 31, 2026. For the quarter, the company announced dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago. For the year, the company expects dividend of JPY 15.00 per share compared to JPY 13.00 per share a year ago.
공시 • Oct 30Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire remaining 99.5% stake in OrganOx Limited from a group of shareholders for $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The transaction will be funded from cash on hand and borrowings. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. The transaction is expected to close in FY2025. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Robbie McLaren, Ross McAloon, Charles Ruck, Elizabeth Richards, Betty Pang, Chad Jennings, Sean Finn, Maj Vaseghi, Kendall Burnett, Hector Armengod, Patrick English, Catherine Hein and Philipp Studt of Latham & Watkins acted as legal counsel to OrganOx in this transaction. Terumo Corporation (TSE:4543) completed the acquisition of remaining 99.5% stake in OrganOx Limited from a group of shareholders on October 29, 2025.
공시 • Oct 24Terumo Interventional Systems Announces its New OPUSWAVE Dual Sensor Imaging System and DualView®? Imaging Catheter Receive FDA 510(k) ClearanceTerumo Interventional Systems (TIS) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its OPUSWAVE®? Dual Sensor Imaging System. The OPUSWAVE Imaging System features the DualView®? imaging catheter, which also received FDA 510(k) clearance. The OPUSWAVE imaging System combines Optical Frequency Domain Imaging (OFDI) and intravascular ultrasound (IVUS) to enable simultaneous views, offering physicians the ability to comprehensively evaluate coronary artery disease (CAD). While this marks Terumo's imaging debut in the US market, the company is already a recognized leader in the single modality imaging space in Japan, where adoption of imaging in percutaneous coronary intervention (PCI) procedures is the highest in the world. What makes the OPUSWAVE Imaging System unique is the DualView imaging catheter, which offers a 150mm maximum pullback length. It also has a 2.6 Fr. imaging profile, 6 Fr. guide compatibility, advanced hydrophilic coating, and a variable pullback speed of up to 40mm/second in dual mode.
공시 • Sep 19Terumo Corporation to Report Q2, 2026 Results on Nov 12, 2025Terumo Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
공시 • Aug 25Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion.Terumo Corporation (TSE:4543) has entered into a definitive agreement to acquire 99.5% stake in OrganOx Limited from a group of shareholders in a transaction valued at $1.5 billion on August 23, 2025. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. For the period ending December 31, 2024, OrganOx Limited reported total revenue of $69.14 million and EBIT of $9.01 million. As of December 31, 2024, OrganOx Limited reported total assets of $96.9 million and total common equity of $71.56 million. The transaction is subject to approval by regulatory board / committee. Perella Weinberg Partners and Piper Sandler served as OrganOx’s financial advisors and Latham & Watkins acted as legal counsel to OrganOx in this transaction.
공시 • Jun 24Terumo Corporation to Report Q1, 2026 Results on Aug 07, 2025Terumo Corporation announced that they will report Q1, 2026 results on Aug 07, 2025
공시 • Jun 03Terumo Neuro Announces EMEA Commercial Availability of the SOFIA™? Flow 88 Neurovascular Aspiration CatheterTerumo Neuro announced the commercial availability of the SOFIA Flow 88 Neurovascular Aspiration Catheter, expanding the company's stroke portfolio with a new large-bore catheter engineered for reliability, procedural flexibility, and physician control. The launch builds on the proven clinical performance and global legacy of the SOFIA™? Catheter line, which has supported more than 500,000 procedures across 170 countries over the past decade. Terumo Neuro is showcasing its complete line of stroke solutions at LINNC Paris this week at Le Carrousel du Louvre, booth number 8. Leveraging more than ten years of neurovascular catheter innovation, physician partnerships and proven clinical performance1-9, the SOFIA™? 88 Neurovascular As inspiration Catheter offers an 0.088-inch inner diameter with proprietary engineering enhancements designed to provide the following benefits: Reach with Confidence - Reliable trackability through challenging anatomy via optimized transition zones and a soft, atraumatic distal tip. Support to Go the Distance - Proximal stability for procedural ease with both short and long sheaths. Atraumatic by Design - Flexibility and reinforcement throughout the entire working length to minimize vessel trauma and support smooth navigation. Engage the Clot with Confidence - Highly compliant proprietary SOFIA tip beyond the marker band expands conforming to the clot. Aspirate with Confidence - Next generation SOFIA technology with nitinol braid and coil reinforcement maintains lumen integrity. The SOFIA™ 88 Neurovascular Aspiration Catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and supports integration into existing aspiration strategies. Clinical evidence from the SOFAST registry & the SESAME trial—evaluating the SOFIA™ Plus 6F as a first-line approach—demonstrated strong results across speed, efficacy, and safety and overall clinical outcomes. The new SOFIA™ 88 Catheter also seamlessly complements the company's broader stroke solution portfolio, offering a fully integrated approach across aspiration, access, retrieval, and navigation: SOFIA™ and SOFIA™ Plus Aspiration Catheters – Renowned for trackability and clinical performance, ERIC™ Retrieval Device – Designed for thrombus control, procedural efficiency, and versatility, BOBBY™ Balloon Guide Catheter – Reliable flow arrest with streamlined preparation, optimized compatibility and next-generation balloon technology, WEDGE™ Microcatheter – A navigation aid that minimizes ledge effect, HEADWAY™ Microcatheters – Low-profile outer diameter, providing versatility, reliability, and fast access, and TRAXCESS™ Guidewires – Soft-tip design for challenging anatomies.
공시 • May 28Terumo Interventional Systems, Division of Terumo Corporation, Announces Commercial Availability of its ROADSAVER Carotid Stent SystemTerumo Interventional Systems (TIS), a division of Terumo Corporation, announced the early commercial availability of its FDA-approved ROADSAVER Carotid Stent System. Indicated for use with the Nanoparasol®? Embolic Protection System, ROADSAVER Stent System addresses carotid artery stenosis in patients with increased risk of adverse events following carotid endarterectomy. ROADSAver Stent System is the only carotid artery stenting (CAS) device with an innovative, dual-layer micromesh. It is designed as a closed-cell stent with the flexibility of an open-cell stent, providing increased flexibility and wall apposition in complex anatomies. It is also the first dual-layer micromesh carotid stent approved in the United States, and the only carotid stent system designed to contain plaque to the vessel wall and prevent plaque protrusion, protecting against distal embolization. Available in sizes from 5 to 10 mm in width and 22 to 47 mm in length, ROADSAVER StENT System has a rapid-exchange shaft length of 143 cm. It is also fully re-sheathable and repositionable - even after 50% of the stent's length is deployed. Another important feature is the product's low-profile 5Fr design, which enhances its crossability. Limited market release of the ROADSAVER CarotID Stent System is planned for summer 2025, with full market release anticipated in fall 2025.
공시 • May 14Terumo Corporation, Annual General Meeting, Jun 24, 2025Terumo Corporation, Annual General Meeting, Jun 24, 2025.
공시 • Apr 17Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business OfficerTerumo Blood and Cell Technologies (Terumo BCT) announced the addition of Patrick Daly as its Chief Business Officer as the company continues to expand its capabilities to meet evolving market segments. Daly joins Terumo BCT with over 30 years of business and healthcare industry experience, both domestically and internationally. Most recently, he built the MedTech Global Data franchise at IQVIA, a provider of technology solutions to the life sciences industry. Daly has spent his career building commercial capabilities to deliver organic and inorganic growth. Before joining IQVIA, he was President and CEO of Cohera Medical, and he remains an independent Board Director for BioStem Technologies. He has held successive senior leadership roles in strategic marketing, sales and business development across various regions and businesses of Johnson &Johnson. He earned his Bachelor of Science in Foreign Area Studies from the U.S. Military Academy at West Point.
공시 • Mar 20Terumo Corporation to Report Fiscal Year 2025 Results on May 14, 2025Terumo Corporation announced that they will report fiscal year 2025 results on May 14, 2025
공시 • Dec 12Terumo Corporation to Report Q3, 2025 Results on Feb 13, 2025Terumo Corporation announced that they will report Q3, 2025 results on Feb 13, 2025
공시 • Dec 03Terumo Interventional Systems Announces Launch of Its R2p Navicross Peripheral Support CatheterTerumo Interventional Systems (TIS), a division of Terumo Corporation announced the launch and commercial availability of its R2P™ NaviCross® peripheral support catheter in the U.S., further expanding the company's radial-to-peripheral (R2P) portfolio. The R2P NaviCross catheter, now available in a 200 cm length, is designed for optimized performance in R2P procedures. Its double-braided, stainless-steel construction is engineered for superior trackability and torque control for lesion crossing in more complex procedures. The new 200 cm R2P NaviCross catheter rounds out the existing R2P portfolio, including the R2P Destination Slender™ guiding sheath, R2P SlenGuide™ guiding catheter, R2P Misago® self-expanding peripheral stent, and R2P Metacross™ RX and R2P Crosstella™ RX dilatation catheters – giving physicians the confidence to complete almost any PAD procedure from the wrist.
공시 • Sep 25Terumo Corporation to Report Q2, 2025 Results on Nov 07, 2024Terumo Corporation announced that they will report Q2, 2025 results on Nov 07, 2024
공시 • Aug 30Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.01% for ¥30,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 15,000,000 shares, representing 1.01% of its issued share capital, for ¥30,000 million. The purpose of the program is to increase shareholder returns, improve capital efficiency, and mitigate the impact on stock supply and demand associated with the offering of our common stock. The repurchased shares will be cancelled. The program will run until December 30, 2024. As of June 30, 2024, the company had 1,484,855,220 shares in issue (excluding treasury stock) and 5,842,060 shares in treasury.
공시 • Jun 03Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024Terumo Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
공시 • May 29Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring SystemTerumo Cardiovascular announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes. The new CDI OneView System measures or displays up to 22 key parameters, the newest of which are measured flow (Q), cardiac index (CI), regional cerebral oxygen saturation (rSO2), oxygen extraction ratio (O2ER), Area Under the DO2 Curve (AUC), and measured arterial oxygen saturation (SaO2). This innovative system offers maximum configurability and flexibility in how the parameters can be viewed and prioritized to best suit clinical needs and preferences, while continuing to provide the critical information on which clinicians have come to rely. New features and functions of Terumo's latest patient parameter monitoring system were influenced by extensive perfusionist input from leading global cardiovascular institutions. In response to the growing needs of healthcare providers, the new CDI OneView System now provides real-time O2ER, CI, VO2 and DO2 information to help perfusionists maintain a safe threshold for those parameters. Independently published and reviewed clinical research indicates that maintaining optimal levels during cardiopulmonary bypass can help to reduce the incidence of acute kidney injury.
공시 • Mar 17Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024Terumo Corporation announced that they will report fiscal year 2024 results on May 14, 2024
공시 • Feb 09Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects revenue to be JPY 906,000 million. Operating profit to be JPY 140,000 million. Profit attributable to owners of parent to be JPY 105,000 million. Earnings per share to be JPY 141.18.
공시 • Feb 07Terumo Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation provided dividend guidance for the fiscal year ending March 31, 2024. For the year, the company expects dividend of JPY 22.00 per share against JPY 21.00 per share paid for the same period a year ago.
공시 • Dec 14+ 2 more updatesShinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024Terumo Corporation announced that it has resolved at the Board of Directors held on December 14, 2023 to change the Executive Officers as. Shinjiro Sato's designation will be changed from President and CEO to the new position of Director and Corporate Advisor (As of April 1, 2024). Shinjiro Sato, with completion of his term, is planned to leave the director's position at the Annual General Meeting of Shareholders to be held on June 26, 2024, and to remain as corporate advisor.
공시 • Dec 03Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024Terumo Corporation announced that they will report Q3, 2024 results on Feb 07, 2024
공시 • Oct 01Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023Terumo Corporation announced that they will report Q2, 2024 results on Nov 14, 2023
공시 • Aug 10Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.Terumo Corporation (TSE:4543) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 0.67% of its issued share capital, for ¥20,000 million. The purpose of the program is to expand shareholder returns and improve capital efficiency. The repurchased shares will be cancelled. The program will run until March 8, 2024. As of June 30, 2023, the company had 744,644,147 shares in issue (excluding treasury stock) and 3,038,393 shares in treasury.
공시 • Jun 21Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023Terumo Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
공시 • May 17+ 1 more updateTerumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Terumo Corporation announced fiscal year-end dividend of JPY 21.00 per share for the fiscal year ended March 31, 2023 against JPY 18.00 per share paid a year ago. Scheduled date to commence dividend payments is June 28, 2023.The company provided second quarter-end dividend guidance for the fiscal year ending March 31, 2024. For the second quarter-end, The company expects to pay JPY 22.00 against JPY 19.00 per share paid a year ago.The company provided year-end dividend guidance for the fiscal year ending March 31, 2024. For the year-end, The company expects to pay JPY 22.00 against JPY 21.00 per share a year ago.
공시 • May 16Terumo Corporation, Annual General Meeting, Jun 27, 2023Terumo Corporation, Annual General Meeting, Jun 27, 2023.
공시 • Feb 09Terumo Corporation Revises Dividend Guidance for Fiscal Year Ending March 31, 2023Terumo Corporation decided at the Board of Directors meeting held on February 9, 2023 to increase the year-end dividend forecast for fiscal year ending March 31, 2023. The details are as follows. The company revised dividend forecast to JPY 21.00 per share compared to the previous guidance of JPY 19.00 per share paid for the same period a year ago. Reason of the Revision: As a measure to secure high profit margins and sustainable growth, Terumo iscommitted to adequately and actively reinvesting its profits to enhance its corporate value continuously. As for the distribution of profits to shareholders, Terumo has been aiming to steadily increase its dividend payouts to shareholders with the target dividend payout ratio of 30% in the mid to long-term.
공시 • Nov 10Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023Terumo Corporation announced that they will report Q3, 2023 results on Nov 10, 2023